Skip to main content

Table 3 Comparisons between mechanically ventilated GBS patients with good and poor short-term prognoses

From: Predictors for mechanical ventilation and short-term prognosis in patients with Guillain-Barré syndrome

Variable Subgroup 1 (n = 34) Subgroup 2 (n = 40) p value
Age (years) 43.9 ± 16.3 41.9 ± 17.3 >0.05
Male 25 (73.5 %) 23 (57.5 %) >0.05
Antecedent infections 28 (82.4 %) 21 (52.5 %) >0.05
Cranial nerve involvement 26 (76.5 %) 24 (60 %) >0.05
 Facial nerve 18 (52.9 %) 22 (55 %) >0.05
 Glossopharyngeal and vagus nerves 18 (52.9 %) 12 (30 %) <0.05
Sensory disturbance 16 (47.1 %) 17 (42.5 %) >0.05
Autonomic dysfunction 3 (8.8 %) 2 (5 %) >0.05
Pain 3 (8.8 %) 4 (10 %) >0.05
Hyporeflexia or areflexia 33 (97.1 %) 39 (97.5 %) >0.05
Hospital stay (days) 31.0 ± 16.1 51.7 ± 31.2 <0.05
Treatment modality    >0.05
 IVIg 18 (52.9 %) 15 (37.5 %)  
 IVIg + intravenous corticosteroids 11 (32.4 %) 18 (45 %)  
 Intravenous corticosteroids 2 (5.9 %) 4 (10 %)  
 Supportive treatment 3 (8.8 %) 3 (7.5 %)  
  1. GBS Guillain-Barré syndrome, IVIg intravenous immunoglobulin, Subgroup 1 mechanically ventilated GBS patients with good short-term prognosis, Subgroup 2 mechanically ventilated GBS patients with poor short-term prognosis